Fundraising FoxFrazier Healthcare Partners — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Gritstone Oncologygritstoneoncology.cominSep 2017
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsBay City CapitalGV (Google Ventures)LAVLilly Asia VenturesAlexandriaThe Column Group+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.